Patents by Inventor Erin M. Allison

Erin M. Allison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating B-cell lymphoma by administering an anti-CD20 antibody
    Patent number: 8329181
    Abstract: The present invention provides methods for treating a B-cell lymphoma in a human subject. The methods of the invention comprise administering to a subject in need thereof an antibody or antigen-binding fragment thereof that specifically binds human CD20. In certain embodiments, the methods of the invention are useful for treating non-Hodgkin's B-cell lymphoma.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: December 11, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Joel H. Martin, Li-Hsien Wang, Sean Stevens, Erin M. Allison
  • METHODS FOR TREATING B-CELL LYMPHOMA BY ADMINISTERING AN ANTI-CD20 ANTIBODY
    Publication number: 20120100145
    Abstract: The present invention provides methods for treating a B-cell lymphoma in a human subject. The methods of the invention comprise administering to a subject in need thereof an antibody or antigen-binding fragment thereof that specifically binds human CD20. In certain embodiments, the methods of the invention are useful for treating non-Hodgkin's B-cell lymphoma.
    Type: Application
    Filed: December 13, 2011
    Publication date: April 26, 2012
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Joel H. Martin, Li-Hsien Wang, Sean Stevens, Erin M. Allison
  • Nucleic acid molecules which encode human anti-CD20 antibodies and methods of use thereof
    Patent number: 8097713
    Abstract: The present invention provides nucleic acid molecules which encode human antibodies or antigen-binding fragments thereof that specifically bind human CD20. Also provided are expression vectors comprising nucleic acid molecules that encode anti-CD20 antibodies, and methods of producing anti-human CD20 antibodies or antigen-binding fragments thereof.
    Type: Grant
    Filed: December 13, 2010
    Date of Patent: January 17, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Joel H. Martin, Li-Hsien Wang, Sean Stevens, Erin M. Allison
  • HUMAN ANTIBODIES TO HUMAN CD20 AND METHOD OF USING THEREOF
    Publication number: 20110081681
    Abstract: A human antibody or antigen-binding fragment of an antibody that specifically binds human CD20 and is capable of inducing complement dependent cytotoxicity (CDC), and is capable of increasing symptom free survival time between about 2-fold to about 9-fold or more, relative to control-treated animals in a mouse model of human lymphoma. The antibody or antigen-binding fragment thereof is useful in a therapeutic method for treating a CD20-mediated disease or condition, such as for example, non-Hodgkin's lymphoma, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, chronic lymphocytic leukemia, and inflammatory diseases.
    Type: Application
    Filed: December 13, 2010
    Publication date: April 7, 2011
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Joel H. Martin, Li-Hsien Wang, Sean Stevens, Erin M. Allison
  • Human antibodies to human CD20 and method of using thereof
    Patent number: 7879984
    Abstract: A human antibody or antigen-binding fragment of an antibody that specifically binds human CD20 and is capable of inducing complement dependent cytotoxicity (CDC), and is capable of increasing symptom free survival time between about 2-fold to about 9-fold or more, relative to control-treated animals in a mouse model of human lymphoma. The antibody or antigen-binding fragment thereof is useful in a therapeutic method for treating a CD20-mediated disease or condition, such as for example, non-Hodgkin's lymphoma, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, chronic lymphocytic leukemia, and inflammatory diseases.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: February 1, 2011
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Joel H. Martin, Li-Hsien Wang, Sean Stevens, Erin M. Allison
  • Human Antibodies to Human CD20 and Method of Using Thereof
    Publication number: 20090035322
    Abstract: A human antibody or antigen-binding fragment of an antibody that specifically binds human CD20 and is capable of inducing complement dependent cytotoxicity (CDC), and is capable of increasing symptom free survival time between about 2-fold to about 9-fold or more, relative to control-treated animals in a mouse model of human lymphoma. The antibody or antigen-binding fragment thereof is useful in a therapeutic method for treating a CD20-mediated disease or condition, such as for example, non-Hodgkin's lymphoma, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, chronic lymphocytic leukemia, and inflammatory diseases.
    Type: Application
    Filed: July 31, 2008
    Publication date: February 5, 2009
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Joel H. MARTIN, Li-Hsien Wang, Sean Stevens, Erin M. Allison